miRNAs are highly conserved class of small ncRNAs whose involvement in human pathophysiologies is extensively investigated. MiR-21 is a well established oncogenic miRNA whose deregulation plays a significant role in onset and progression of cancer. The need of novel approaches to downregulate miR-21 is rapidly expanding. Potent inhibition of miR-21 is achieved by chemically modified 2′-O-methyl RNA oligonucleotide. The serinol capping at 3′ and 5′ends and the interspersed 2′-O-(R-2-amino-3-methoxypropyl) uridine units enhance the nuclease resistance and efficacy of 2′-O-methyl RNA for the inhibition of miR-21. This represents a simple and novel modification for developing oligonucleotide-based therapeutics.
Get full access to this article
View all access options for this article.
References
1.
BartelDP. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136:215–233.
2.
LewisBP, ShihIH, Jones-RhoadesMW, BartelDP and BurgeCB. (2003). Prediction of mammalian microRNA targets. Cell, 115:787–798.
3.
AmbrosV. (2004). The functions of animal microRNAs. Nature, 431:350–355.
4.
ArdekaniAM and NaeiniMM. (2010). The role of microRNAs in human diseases. Avicenna J Med Biotechnol, 2:161–179.
5.
ObernostererG, MartinezJ and AleniusM. (2007). Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections. Nat Protoc, 2:1508–1514.
6.
SilahtarogluAN, NoltingD, DyrskjotL, BerezikovE, MollerM, TommerupN and KauppinenS. (2007). Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc, 2:2520–2528.
7.
ParkJ and YeoJS. (2014). Colorimetric detection of microRNA miR-21 based on nanoplasmonic core-satellite assembly. Chem Commun (Camb), 50:1366–1368.
8.
LanfordRE, Hildebrandt-EriksenES, PetriA, PerssonR, LindowM, MunkME, KauppinenS and HOrum. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 327:198–201.
9.
van RooijE, PurcellAL and LevinAA. (2012). Developing microRNA therapeutics. Circ Res, 110:496–507.
10.
StenvangJ, PetriA, LindowM, ObadS and Kauppinen.S (2012). Inhibition of microRNA function by antimiR oligonucleotides. Silence, 3:1.
11.
EsauC, DavisS, MurraySF, YuXX, PandeySK, PearM, WattsL, BootenSL, GrahamM, et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 3:87–98.
12.
MeisterG, LandthalerM, DorsettY and TuschlT. (2004). Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA, 10:544–550.
13.
TakahashiM, YamadaN, HatakeyamaH, MurataM, SatoY, MinakawaN, HarashimaH and MatsudaA. (2013). In vitro optimization of 2′-OMe-4′-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic Acids Res, 41:10659–10667.
14.
DavisS, ProppS, FreierSM, JonesLE, SerraMJ, KinbergerG, BhatB, SwayzeEE, BennettCF and EsauC. (2009). Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res, 37:70–77.
15.
OhSY, JuY and ParkH. (2009). A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol Cells, 28:341–345.
16.
BrownPN and YinH. (2013). PNA-based microRNA inhibitors elicit anti-inflammatory effects in microglia cells. Chem Commun (Camb), 49:4415–4417.
17.
PetersenM and WengelJ. (2003). LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol, 21:74–81.
18.
ElmenJ, LindowM, SchutzS, LawrenceM, PetriA, ObadS, LindholmM, HedtjarnM, HansenHF, et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature, 452:896–899.
19.
HutvagnerG, SimardMJ, MelloCC and Zamore.PD (2004). Sequence-specific inhibition of small RNA function. PLoS Biol, 2:E98.
20.
BlechingerJ, PieperH, MarzenellP, KovbasyukL, ServaA, StarkuvieneV, ErfleH and MokhirA. (2013). Short, terminally modified 2′-OMe RNAs as inhibitors of microRNA. Chem Commun (Camb), 49:7397–7399.
21.
MajlessiM, NelsonNC and BeckerMM. (1998). Advantages of 2′-O-methyl oligoribonucleotide probes for detecting RNA targets. Nucleic Acids Res, 26:2224–2229.
22.
LennoxKA and BehlkeMA. (2010). A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res, 27:1788–1799.
23.
LennoxKA, OwczarzyR, ThomasDM, WalderJA and Behlke.MA (2013). Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol Ther Nucleic Acids, 2:e117.
24.
KotikamV and KumarVA. (2013). Synthesis and properties of 2′-O-R- and S-(2-amino-3-methoxy)propyl (R-AMP and S-AMP) nucleic acids. Tetrahedron, 69:6404–6408.
25.
KotikamV, ArzumanovAA, GaitMJ and KumarVA. (2013). Enhanced splice correction by 3′, 5′-serinol and 2′-(omega-O-methylserinol) guarded OMe-RNA/DNA mixmers in cells. Artif DNA PNA XNA, 4:77–83.
26.
SanghviYS. (2011). A status update of modified oligonucleotides for chemotherapeutics applications. Curr Protoc Nucleic Acid Chem, 4:Unit 4:1.1–22.
27.
LivakKJ and SchmittgenTD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25:402–408.
28.
LiangCC, ParkAY and GuanJL. (2007). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc, 2:329–333.
29.
PfafflMW. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 29:e45.
30.
MedinaPP, NoldeM and SlackFJ. (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 467:86–90.
MengF, HensonR, Wehbe-JanekH, GhoshalK, JacobST and PatelT. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133:647–658.
33.
FrankelLB, ChristoffersenNR, JacobsenA, LindowM, KroghA and LundAH. (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem, 283:1026–1033.
34.
BaekD, VillenJ, ShinC, CamargoFD, GygiSP and BartelDP. (2008). The impact of microRNAs on protein output. Nature, 455:64–71.
35.
SelbachM, SchwanhausserB, ThierfelderN, FangZ, KhaninR and RajewskyN. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 455:58–63.
36.
ZhuS, WuH, WuF, NieD, ShengS and MoYY. (2008). MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res, 18:350–359.
37.
PriceJE, PolyzosA, ZhangRD and DanielsLM. (1990). Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res, 50:717–721.
38.
LevinAA. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta, 1489:69–84.
39.
AmarzguiouiM, HolenT, BabaieE and PrydzH. (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res, 31:589–595.
40.
StratfordS, StecS, JadhavV, SeitzerJ, AbramsM and BeverlyM. (2008). Examination of real-time polymerase chain reaction methods for the detection and quantification of modified siRNA. Anal Biochem, 379:96–104.
41.
LennoxKA and BehlkeMA. (2011). Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther, 18:1111–1120.
42.
FreierSM and AltmannKH. (1997). The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res, 25:4429–4443.
43.
KrutzfeldtJ, KuwajimaS, BraichR, RajeevKG, PenaJ, TuschlT, ManoharanM and StoffelM. (2007). Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res, 35:2885–2892.
44.
TorresAG, FabaniMM, VigoritoE and GaitMJ. (2011). MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA, 17:933–943.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
